Rallybio Corporation — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report rather than a quarterly filing; fourth-quarter developments are included where disclosed. Rallybio is a clinical-stage biotechnology company focused on severe and rare diseases. It has no approved products and has never generated product revenue.
Business Context and Pipeline
- RLYB212: Anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Phase 1 and Phase 1b studies were completed. Management plans to initiate a Phase 2 study in expectant mothers in the second half of 2024, subject to regulatory discussions.
- RLYB116: Subcutaneous C5 inhibitor for complement-mediated diseases, including potential applications in generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria and antiphospholipid syndrome. Phase 1 was completed; further Phase 2 development was deferred while manufacturing improvements are pursued.
- Other programs: RLYB114 is being evaluated with EyePoint for sustained intraocular delivery; RLYB331 remains preclinical; the Exscientia joint venture is pursuing an ENPP1 inhibitor for hypophosphatasia; and AbCellera is collaborating on additional rare-disease antibody programs.
- The Company employed 43 full-time employees as of December 31, 2023. In February 2024, it announced a workforce reduction of approximately 45% to prioritize clinical-stage assets.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $53.5 million | $40.7 million | +$12.9 million |
| General and administrative expense | $25.4 million | $27.2 million | -$1.8 million |
| Total operating expenses | $78.9 million | $67.9 million | +$11.0 million |
| Other income, net | $6.4 million | $2.3 million | +$4.1 million |
| Net loss | $74.6 million | $66.7 million | Loss increased $7.9 million |
| Net loss per share | $1.84 | $2.09 | Improved due to higher share count |
| Net cash used in operating activities | $60.3 million | $57.3 million | Use increased $3.0 million |
Margins and profitability: Revenue-based margins are not meaningful because the Company has no product sales. Operating loss was $78.9 million, and net loss represented the full year’s operating profile. The accumulated deficit reached $235.2 million at December 31, 2023.
- Cash, cash equivalents and marketable securities totaled $109.9 million at year-end, consisting of $24.5 million of cash and cash equivalents and $85.4 million of marketable securities.
- Management believes existing liquidity can fund operating expenses and capital requirements into the middle of 2026, but acknowledges that the estimate could change and that additional capital will be required to fund programs through regulatory approval and commercialization.
- Rallybio reported no material debt or credit facility. Total liabilities were $9.4 million, primarily accounts payable, accrued expenses and operating lease liabilities.
- Net cash provided by investing activities was $27.7 million, primarily reflecting maturities of marketable securities. Financing activities provided $0.1 million in 2023, compared with $51.1 million in 2022 from the follow-on offering.
- Operating lease obligations totaled $0.4 million, with $0.2 million due within one year.
Material Changes Versus the Prior Comparable Period
- Research and development spending increased 31.6% to $53.5 million, driven primarily by higher RLYB212 clinical and manufacturing costs, as well as increased RLYB116 and RLYB331 spending.
- RLYB212 became the clear development priority. Fourth-quarter 2023 multiple-dose data supported a once-monthly regimen for the planned Phase 2 study. Earlier Phase 1b data showed mean platelet elimination half-lives of 5.8 hours and 1.5 hours at the 0.09 mg and 0.29 mg doses, respectively, versus 71.7 hours for placebo.
- RLYB116 Phase 1 multiple-dose data showed more than 93% sustained mean reduction in free C5 at a 100 mg once-weekly dose, including before the Day 29 dose. However, the Company decided not to immediately initiate Phase 2 and instead prioritized manufacturing improvements.
- Interest income increased to $6.1 million from $2.0 million because of higher yields on marketable securities.
- The loss on the Exscientia joint venture increased to $2.0 million from $1.1 million, and Rallybio contributed approximately $2.3 million to the joint venture in 2023.
- Share-based compensation increased to $10.9 million from $9.5 million.
- In February 2024, management announced the portfolio prioritization and workforce reduction. Expected cash charges were approximately $3.3 million, excluding share-based compensation, and were expected to be recognized substantially in the first quarter of 2024.
Guidance, Outlook, Commentary and Risks
- Management expects to initiate the RLYB212 Phase 2 study in the second half of 2024 and continue the FNAIT natural history study, which had screened approximately 9,400 expectant mothers as of March 1, 2024.
- Manufacturing work for RLYB116 is expected to be completed in the second half of 2024. Management intends to seek a partner or non-dilutive financing to advance the program while conserving capital.
- RLYB331 preclinical data and an update on the EyePoint collaboration were expected in the first half of 2024; an update on the Exscientia program was expected in the second half of 2024.
- Rallybio relies extensively on contract research organizations, clinical sites, contract manufacturers and third-party diagnostic providers. It has no internal manufacturing facilities and no current commercial manufacturing commitments.
- Key development risks include failure to reproduce early clinical results, patient enrollment challenges in rare diseases, adverse events, regulatory disagreement over trial designs or natural-history data, companion-diagnostic requirements, manufacturing delays and competition.
- RLYB116 carries potential complement-inhibition risks, including increased susceptibility to infection. In the Phase 1 multiple-dose study, injection-site reactions were generally mild, gastrointestinal events increased with dose, and one participant with a history of hepatitis experienced severe liver-function-test elevation that led to discontinuation.
- The Company expects continued operating losses and negative cash flows. Its runway estimate depends on development costs, trial timing, regulatory requirements and the success of planned cost-preservation measures.
- Potential future financing may dilute stockholders, impose debt covenants or require Rallybio to surrender rights to product candidates or intellectual property.
- The filing states that no material litigation or cybersecurity incident had occurred as of the filing date. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2023.
Most Important Facts for Investors to Verify
- Whether the RLYB212 Phase 2 trial actually began in the second half of 2024 and whether regulatory authorities accept the proposed design, screening approach and natural-history control data.
- Updated cash usage, workforce-reduction charges and whether the stated cash runway to mid-2026 remains credible after advancing RLYB212.
- RLYB116 manufacturing results, tolerability at higher exposure levels and whether a partner or non-dilutive financing is secured.
- Whether early RLYB212 and RLYB116 findings translate into safety and efficacy in pregnant patients or disease populations rather than healthy volunteers.
- Potential dilution from the $100 million at-the-market facility, outstanding pre-funded warrants for up to 3.33 million shares and equity compensation awards.
- Milestone, royalty and other contingent obligations under agreements with Prophylix, Sobi, Affibody, Sanofi, Exscientia, AbCellera and other collaborators.
- The need for companion diagnostics or specialized delivery systems, their regulatory status and their impact on commercialization costs and market access.